FDA to review removal of Eli Lilly weight loss drug from shortage list
The U.S. Food and Drug Administration (FDA) has agreed to reconsider its decision to remove tirzepatide, the active ...
US FDA to reconsider decision barring compounded versions of Lilly weight loss drug
The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from ...
WEHT Evansville on MSN16h
Gov. Holcomb to lead U.S. delegation to Greece
Governor Eric J. Holcomb says he will lead an international trip to Greece next week at the invitation of the Council of ...
GlobalData on MSN21h
XtalPi’s AI biologics discovery platform licensed to Janssen Biotech
XtalPi, an AI drug discovery company and subsidiary of Ailux Biologics, has entered a licensing agreement with Janssen ...
Eli Lilly and Company (LLY): Among the Most Promising Growth Stocks According to Hedge Funds
We recently compiled a list of the 10 Most Promising Growth Stocks According to Hedge Funds. In this article, we are going to ...
STAT13h
In stark reversal, FDA to reconsider removal of Eli Lilly weight loss drug from shortage list
The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, from its ...
Ibj.com20h
Why Lilly is pouring billions into LEAP
In recent years, the pharmaceutical manufacturer has seen dizzying growth in its pipeline for a wide range of diseases. And ...
Hoodline18h
Michigan Attorney General Fights to Revoke Decades-Old Rulings Shielding Pharma Giant Eli Lilly from Insulin Pricing Scrutiny
Michigan's Supreme Court reexamines rulings that may affect how the state's consumer protection laws apply to insulin pricing ...
FiercePharma23h
Lilly's manufacturing splurge continues with $200M expansion in China
Lilly has earmarked $200 million for the upgrade, a company spokesperson confirmed to Fierce Pharma. The new project will ...
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's dominance while addressing scalability and pricing concerns.
My antidepressants left me with no feeling in my genitals
Daryl Brown, who was prescribed the antidepressant Seroxat in childhood because of his Tourette’s syndrome and OCD, tells ...
Top WA provider for minor gender reassignment procedures previously fined $5 million
A Washington-based surgery center ranked by a nonprofit among the top in the state for minor gender reassignment surgeries ...